Ardelyx
Ardelyx is dedicated to creating a healthier tomorrow by delivering first-in-class medicines to patients with unmet medical needs. The company focuses on therapeutic areas such as chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation, working closely with patients, caregivers, and healthcare professionals to improve outcomes and set new standards in patient care, community engagement, and product innovation.
Industries
Nr. of Employees
medium (51-250)
Ardelyx
400 Fifth Avenue, Suite 210, Waltham, MA 02451
Patents
Hormone receptor modulators for treating metabolic conditions and disorders
US-12209088-B2
View DetailsCompounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US-12016856-B2
View Details
Hormone receptor modulators for treating metabolic conditions and disorders
US-12209088-B2
View DetailsCompounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US-12016856-B2
View DetailsProducts
IBSRELA
Approved oral therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in indicated populations; prescribing information and boxed warning available in official product documentation.
XPHOZAH
Approved therapy for the improvement of hyperphosphatemia in adult patients with chronic kidney disease on dialysis; prescribing information available.
Patient access and support program (digital)
A patient services program providing access, affordability, and care-coordination support for patients prescribed company medicines, delivered via digital tools and phone support.
IBSRELA
Approved oral therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in indicated populations; prescribing information and boxed warning available in official product documentation.
XPHOZAH
Approved therapy for the improvement of hyperphosphatemia in adult patients with chronic kidney disease on dialysis; prescribing information available.
Patient access and support program (digital)
A patient services program providing access, affordability, and care-coordination support for patients prescribed company medicines, delivered via digital tools and phone support.
Services
A digital-forward, high-touch program that provides patient access and affordability support and integrates with medical office workflows and provider communications.
Provision of information for patients and healthcare professionals about ongoing clinical trials and pathways for patient participation.
Selective funding and grants for independent medical education and community or healthcare-related charitable organizations, managed via a grants portal and internal review procedures.
Structuring and managing licensing agreements for development and commercialization in territories outside the primary market.
A digital-forward, high-touch program that provides patient access and affordability support and integrates with medical office workflows and provider communications.
Provision of information for patients and healthcare professionals about ongoing clinical trials and pathways for patient participation.
Selective funding and grants for independent medical education and community or healthcare-related charitable organizations, managed via a grants portal and internal review procedures.
Structuring and managing licensing agreements for development and commercialization in territories outside the primary market.
Expertise Areas
- Mechanism-based small-molecule drug discovery
- Early drug development and IND/NDA preparation
- Clinical trial management and patient recruitment
- Commercialization and market access for specialty therapeutics
Key Technologies
- Mechanism-driven small-molecule discovery
- Non-absorbed/minimally systemic small-molecule therapeutics
- Digital patient services platform
- Clinical trial management systems
News & Updates
An award created to recognize passionate supporters of patients living with chronic kidney disease who champion the need for innovation and the need to improve health incomes. Named after Derek Forfang, a person who suffered from CKD and passed away in 2023, and who was a founding member of the Ardelyx Patient Advisory Council.
An award created to recognize passionate supporters of patients living with chronic kidney disease who champion the need for innovation and the need to improve health incomes. Named after Derek Forfang, a person who suffered from CKD and passed away in 2023, and who was a founding member of the Ardelyx Patient Advisory Council.